AbbVie

ABBV67

S&P500

$168.29arrow_drop_up0.31%$0.53

S&P500

ABBV67

$168.29

arrow_drop_up0.31%$0.53

S&P500

Performance History

Key Stats
Open	$165.27
Prev. Close	$166.28
EPS	2.87

Next Earnings Date	May 16, 2025

	LOW	HIGH
Day Range	163.90	167.02
52 Week Range	135.85	207.59

Ratios







EPS	2.87

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About AbbVie (ABBV)

AbbVie Inc. (ABBV) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of advanced therapies for a wide range of medical conditions. The company was established in 2013 as a spin-off from Abbott Laboratories, and it has since emerged as a leader in the pharmaceutical industry. AbbVie is best known for its flagship product, Humira, which is the world's top-selling prescription medicine. Humira is used to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease. In addition to Humira, AbbVie has a diverse portfolio of innovative drugs that address other therapeutic areas, such as oncology, immunology, and neuroscience.

AbbVie's success is driven by its strong research and development capabilities, as well as its focus on strategic acquisitions and partnerships. The company invests heavily in scientific research and has a robust pipeline of potential new drugs. AbbVie also seeks to expand its portfolio through targeted acquisitions of complementary companies. For example, in 2019, AbbVie completed its acquisition of Allergan plc, a leading global pharmaceutical company, to enhance its position in the aesthetics and eye care markets. This acquisition added several popular brands to AbbVie's portfolio, such as Botox and Juvederm.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—General
CEO: Mr. Richard A. Gonzalez
Headquarters: North Chicago
Employees: 50000
Exchange: NYSE

Keep an eye on AbbVie

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is AbbVie 's (ABBV) price per share?

The current price per share for AbbVie (ABBV) is $168.29. The stock has seen a price change of $0.53 recently, indicating a 0.32% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for AbbVie (ABBV)?

For AbbVie (ABBV), the 52-week high is $207.59, which is 23.35% from the current price. The 52-week low is $135.85, the current price is 23.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is AbbVie (ABBV) a growth stock?

AbbVie (ABBV) has shown an average price growth of -7.34% over the past three years. It has received a score of 70 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying AbbVie as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is AbbVie (ABBV) stock price performance year to date (YTD)?

As of the latest data, AbbVie (ABBV) has a year-to-date price change of 5.3%. Over the past month, the stock has experienced a price change of -9.78%. Over the last three months, the change has been -14.2%. Over the past six months, the figure is 2.27%. Looking at a longer horizon, the five-year price change stands at 92.99%.

help

Is AbbVie (ABBV) a profitable company?

AbbVie (ABBV) has a net income of $4.88B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 83.84% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 28.93% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $54.32B, although specific revenue growth data is currently not available. The gross profit is $45.54B. Operating income is noted at $12.76B. Furthermore, the EBITDA is $19.46B.

help

What is the market capitalization of AbbVie (ABBV)?

AbbVie (ABBV) has a market capitalization of $296.46B. The average daily trading volume is 168.22, indicating the stock's liquidity and investor engagement.